Patents by Inventor Mei Lai

Mei Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20150344441
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: August 10, 2015
    Publication date: December 3, 2015
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20150290228
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of diffuse large B-cell lymphoma, follicular lymphoma, or mantel cell lymphoma, which comprises administering to a human having diffuse large B-cell lymphoma, follicular lymphoma, or mantel cell lymphoma a therapeutically effective amount of 5-azacytidine, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and optionally administering therapeutically effective amounts of one or more additional active agents.
    Type: Application
    Filed: January 9, 2015
    Publication date: October 15, 2015
    Inventors: Jay T. BACKSTROM, Jeffrey B. ETTER, Mei LAI
  • Salts of an epidermal growth factor receptor kinase inhibitor
    Patent number: 9108927
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 18, 2015
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • Solid forms of an epidermal growth factor receptor kinase inhibitor
    Patent number: 9056839
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 16, 2015
    Assignee: Celgene Avilomics Research, Inc.
    Inventor: Mei Lai
  • ISOTOPOLOGUES OF 5-AZACYTIDINE
    Publication number: 20150056280
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: August 19, 2014
    Publication date: February 26, 2015
    Inventors: John F. TRAVERSE, William W. LEONG, Jeffrey B. ETTER, Mei LAI, Jay Thomas BACKSTROM
  • ROMIDEPSIN FORMULATIONS AND USES THEREOF
    Publication number: 20150051157
    Abstract: Provided herein are formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation is a combination of romidepsin and mannitol.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 19, 2015
    Inventors: Lianfeng HUANG, Ho-Wah HUI, Victor PEYKOV, Willard R. FOSS, Vijay NARINGREKAR, Mei LAI
  • Oral formulations of cytidine analogs and methods of use thereof
    Patent number: 8846628
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 30, 2014
    Assignee: Celgene Corporation
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20130267530
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Inventor: Mei Lai
  • SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR
    Publication number: 20130267531
    Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Applicant: Celgene Avilomics Research, Inc.
    Inventors: Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
  • Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients
    Patent number: 8455196
    Abstract: The preset invention relates to a biomarker for identifying the subgroup of early-stage lung adenocarcinoma patients in early-stage non-small cell lung cancer (NSCLC), which is T-lymphokine-activated killer cell-originated protein kinase (TOPK), and a therapeutic target for lung cancer.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: June 4, 2013
    Inventor: Jin-Mei Lai
  • BIOMARKER FOR IDENTIFYING SUBGROUP OF EARLY-STAGE LUNG ADENOCARCINOMA PATIENTS
    Publication number: 20120302624
    Abstract: The preset invention relates to a biomarker for identifying the subgroup of early-stage lung adenocarcinoma patients in early-stage non-small cell lung cancer (NSCLC), which is T-lymphokine-activated killer cell-originated protein kinase (TOPK), and a therapeutic target for lung cancer.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventor: Jin-Mei Lai
  • PHARMACEUTICAL COMPOSITIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20120196823
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for parenteral administration. Also provided are methods of preparing the compositions and methods of treating diseases and disorders using the compositions provided herein.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 2, 2012
    Applicant: Celgene Corporation
    Inventors: Anthony TUTINO, Mei LAI, Jeffrey B. ETTER
  • ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
    Publication number: 20090286752
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Application
    Filed: May 14, 2009
    Publication date: November 19, 2009
    Inventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • ORAL PERTUSSIS VACCINE AND METHOD FOR PRODUCING PERTUSSIS VACCINE
    Publication number: 20080305124
    Abstract: The present invention is related to an oral pertussis vaccine and a method for producing pertussis vaccine, wherein the oral pertussis vaccine comprises amino acid sequence of 1094 to 1279 (SEQ ID NO.1) of filamentous hemagglutinin. The method for producing pertussis vaccine comprises following steps: constructing a vector comprising amino acid sequence of 1094 to 1279 (SEQ ID NO. 1) of filamentous hemagglutinin; transforming the vector into Agrobacterium successfully; co-culturing vector containing Agrobacterium with plant; and obtaining successfully a transformed plant as the vaccine. The present invention is also related to a polypeptide containing SEQ ID NO.1.
    Type: Application
    Filed: March 11, 2008
    Publication date: December 11, 2008
    Applicant: AGRICULTURE AND FOOD AGENCY, COUNCIL OF AGRICULTURE, EXECUTIVE YUAN
    Inventors: Shih-Tong Jeng, Bor-Luen Chiang, Meng-Huei Chang, Hsi-Mei Lai
  • 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
    Patent number: 4429148
    Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.
    Type: Grant
    Filed: September 25, 1981
    Date of Patent: January 31, 1984
    Assignee: American Cyanamid Company
    Inventors: Middleton B. Floyd, Jr., Martin J. Weiss, Charles V. Grudzinskas, Sow-Mei Lai Chen
  • 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners
    Patent number: 4281153
    Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.
    Type: Grant
    Filed: January 17, 1980
    Date of Patent: July 28, 1981
    Assignee: American Cyanamid
    Inventors: Middleton B. Floyd, Jr., Martin J. Weiss, Charles V. Grudzinskas, Sow-Mei Lai Chen
  • 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic acids and congeners
    Patent number: 4061670
    Abstract: This disclosure describes novel 15-deoxy-16-hydroxy-16-substituted prostanoic acids and congeners thereof having utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.
    Type: Grant
    Filed: July 19, 1976
    Date of Patent: December 6, 1977
    Assignee: American Cyanamid Company
    Inventors: Middleton Brawner Floyd, Jr., Martin Joseph Weiss, Charles Vincent Grudzinskas, Sow-Mei Lai Chen